Moderna, the biotechnology firm that gained global prominence for its mRNA-based COVID-19 vaccine, is embarking on a significant strategic pivot,…
Read More
A GLP-1 bone study shows why matching matters in real-world evidence
The landscape of medical research is increasingly shaped by real-world evidence (RWE), drawing insights from the vast repositories of patient…
Read More
Ginkgo, Tangible and Inductive Bio Launch ADME-One Platform to Revolutionize Early Drug Discovery Decisions with AI and Automation
A significant shift is underway in small-molecule drug discovery, as a new collaboration between Ginkgo Datapoints, Tangible Scientific, and Inductive…
Read More
Blazing New Paths for American Biotech Amidst Evolving Global Landscape and Intense Competition
For several years, the pursuit of success for American biotechnology firms has grown increasingly arduous. Even in the more robust…
Read More
Boehringer Ingelheim Eyes MASH as the Next Front for Survodutide, a GLP-1/Glucagon Receptor Dual Agonist
For decades, fatty liver disease, specifically its more severe inflammatory manifestation known as metabolic dysfunction-associated steatohepatitis (MASH), remained a significant…
Read More
ADA Conference Highlights: GLP-1 Innovations Reshape Metabolic Treatment Landscape Amidst Unprecedented Scientific Advocacy Protest
The annual scientific sessions of the American Diabetes Association (ADA) this week served as a dual-faceted arena, showcasing both groundbreaking…
Read More
J&J Poster Puts Spravato Remission Data at Center of Treatment-Resistant Depression Growth Push
More than six decades after Calvin Stevens first synthesized ketamine at Parke-Davis in 1962 while diligently searching for a safer…
Read More
CNPV: A gamechanger for the pharma industry or simply more chaos?
The United States Food and Drug Administration (FDA) embarked on a bold new initiative in June 2025 with the announcement…
Read More
Calderasib’s Real Innovation: Designed for Combination, Not Raw Potency
Merck’s investigational KRAS G12C inhibitor, calderasib, is making headlines not for its standalone potency but for a strategically different attribute:…
Read More
FUJIFILM Biotechnologies COO Maja Herold Pedersen on AI, autonomy and the path from quality to operations
FUJIFILM Biotechnologies, a prominent contract development and manufacturing organization (CDMO), is currently navigating an unprecedented phase of strategic expansion, marked…
Read More
